I'm LongbridgeAI, I can summarize articles.Novavax (NVAX) rose 7.32% this week to close at $10.11, while the S&P 500 slipped 0.08%, meaning the stock outperformed by roughly 7.4 percentage points. The week was choppy but tilted higher: Monday and Tuesday held between $9.13 and $9.60, Thursday spiked to $10.38 on heavier turnover, and Friday settled at $10.11. There was no major catalyst this week. Daily volume averaged 5.9m shares, about 59% above the median, driven by Thursday and Friday.
The Week
Novavax (NVAX) rose 7.32% this week to close at $10.11, while the S&P 500 slipped 0.08%, meaning the stock outperformed by roughly 7.4 percentage points. The week was choppy but tilted higher: Monday and Tuesday held between $9.13 and $9.60, Thursday spiked to $10.38 on heavier turnover, and Friday settled at $10.11. There was no major catalyst this week. Daily volume averaged 5.9m shares, about 59% above the median, driven by Thursday and Friday.\n\n## Analyst Ratings\n\nNine analysts cover the stock: five rate it buy, one hold, two underperform, and one sell. The consensus rating is buy, with a consensus target of $14.00, roughly 38.5% above the latest price. Targets range from $7.00 to $25.00, so dispersion is wide. The stock ranks 147th out of 501 in its biotech industry, below the peer median.\n\n## The Week Ahead\n\nNo Novavax earnings are scheduled next week. On the macro side, keep an eye on the Richmond Fed composite index on Tuesday 22 September, and weekly jobless claims plus new home sales on Thursday 24 September. On the stock itself, watch for any follow-through from the expanded Mabion collaboration announced this week.\n\nThis article is generated by LongbridgeAI from market data, for information only and not investment advice.